154 related articles for article (PubMed ID: 36123923)
21. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
[TBL] [Abstract][Full Text] [Related]
22. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.
Dahan K; Debiec H; Plaisier E; Cachanado M; Rousseau A; Wakselman L; Michel PA; Mihout F; Dussol B; Matignon M; Mousson C; Simon T; Ronco P;
J Am Soc Nephrol; 2017 Jan; 28(1):348-358. PubMed ID: 27352623
[TBL] [Abstract][Full Text] [Related]
23. Crescentic glomerulonephritis and membranous nephropathy: a rare coexistence.
Balafa O; Kalaitzidis R; Liapis G; Xiromeriti S; Zarzoulas F; Baltatzis G; Elisaf M
Int Urol Nephrol; 2015 Aug; 47(8):1373-7. PubMed ID: 26092054
[TBL] [Abstract][Full Text] [Related]
24. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
[TBL] [Abstract][Full Text] [Related]
25. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
Front Immunol; 2022; 13():898811. PubMed ID: 35967405
[TBL] [Abstract][Full Text] [Related]
26. Proteinuria in a patient with Graves' disease: Answers.
Dagdeviren Cakir A; Canpolat N; Saygili S; Kilicaslan I; Turan H; Ercan O; Evliyaoglu O
Pediatr Nephrol; 2019 Aug; 34(8):1383-1385. PubMed ID: 30843111
[No Abstract] [Full Text] [Related]
27. Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?
Esposito P; Grosjean F; Mangione F; Domenech MV; Rampino T
Clin Exp Nephrol; 2018 Feb; 22(1):208-209. PubMed ID: 28660444
[No Abstract] [Full Text] [Related]
28. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Boyer-Suavet S; Andreani M; Lateb M; Savenkoff B; Brglez V; Benzaken S; Bernard G; Nachman PH; Esnault V; Seitz-Polski B
Front Immunol; 2019; 10():3069. PubMed ID: 31998325
[TBL] [Abstract][Full Text] [Related]
29. Primary membranous nephropathy: comprehensive review and historical perspective.
Keri KC; Blumenthal S; Kulkarni V; Beck L; Chongkrairatanakul T
Postgrad Med J; 2019 Jan; 95(1119):23-31. PubMed ID: 30683678
[TBL] [Abstract][Full Text] [Related]
30. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
31. Primary membranous nephropathy presenting with crescentic glomerulonephritis 25 years after initial presentation: A case report
.
Massicotte-Azarniouch D; Barbour S; Blanco P; Clark EG
Clin Nephrol; 2018 Oct; 90(4):291-295. PubMed ID: 29932409
[TBL] [Abstract][Full Text] [Related]
32. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
Anjum N; Nabi Z; Alam MA
J Ayub Med Coll Abbottabad; 2019; 31(2):265-268. PubMed ID: 31094128
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological features and prognosis of primary membranous nephropathy in combination with crescent.
Pan Y; Liu L; Chen W; Yang H; Zhang J; Wang Y
Int Urol Nephrol; 2023 Jun; 55(6):1523-1530. PubMed ID: 36622536
[TBL] [Abstract][Full Text] [Related]
34. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
Hudson R; Rawlings C; Mon SY; Jefferis J; John GT
BMC Nephrol; 2022 Apr; 23(1):134. PubMed ID: 35392837
[TBL] [Abstract][Full Text] [Related]
35. Circulating antibodies to α-enolase and phospholipase A
Kimura Y; Miura N; Debiec H; Morita H; Yamada H; Banno S; Ronco P; Imai H
Clin Exp Nephrol; 2017 Feb; 21(1):117-126. PubMed ID: 26830547
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy of Rituximab in the Treatment of Membranous Nephropathy.
Maharjan R; Wang JW; Shrestha IK
J Nepal Health Res Counc; 2021 Jan; 18(4):580-587. PubMed ID: 33510493
[TBL] [Abstract][Full Text] [Related]
37. Treatment of exostosin 1-associated membranous lupus nephritis with multiple low doses of rituximab: A case report.
Li L; Yang Z; Tao T; Yang M; Hu ZX
Medicine (Baltimore); 2021 Mar; 100(9):e24887. PubMed ID: 33655949
[TBL] [Abstract][Full Text] [Related]
38. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.
Wang X; Cui Z; Zhang YM; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Zhou FD; Zhao MH
Nephrol Dial Transplant; 2018 Sep; 33(9):1558-1563. PubMed ID: 29149305
[TBL] [Abstract][Full Text] [Related]
39. Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab.
Plaisier E; Not A; Buob D; Ronco P; Debiec H
Kidney Int; 2021 Dec; 100(6):1342-1344. PubMed ID: 34802560
[No Abstract] [Full Text] [Related]
40. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
